Stifel Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $41
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino maintains a Buy rating on Syndax Pharmaceuticals and raises the price target from $40 to $41.
October 14, 2024 | 1:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Bradley Canino has reiterated a Buy rating for Syndax Pharmaceuticals and increased the price target from $40 to $41, indicating a positive outlook.
The increase in price target from $40 to $41 by Stifel suggests a positive outlook for Syndax Pharmaceuticals. The Buy rating indicates confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100